MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab by Carlo Bifulco et al.
POSTER PRESENTATION Open Access
MISIPI study: Melanoma ImmunoScore evaluation
in patients treated with IPIlimumab
Carlo Bifulco1*, Marilena Capone2, Zip Feng1, Gabriele Madonna2, Ester Simeone2, Marcello Curvietto2,
Nicola Mozzillo2, Gennaro Ciliberto2, Gerardo Botti2, Bernard A Fox1, Paolo A Ascierto2
From Melanoma Bridge meeting 2013
Naples, Italy. 5-8 December 2013
Background
Increasing evidence has supported the hypothesis that
cancer development is influenced by the host immune
system. Immune infiltrates of the primary tumors and
metastases are independent prognostic biomarkers and
may represent predictive factors, suggesting that pre-
therapeutic immune response determines the efficacy of
different immunotherapies [1]. An immune-classification
of tumors based on a scoring system of density and
location of immune-cells within the tumor has been
recently proposed in human colorectal cancers, where a
high density of CD3+, CD8+ memory T lymphocytes in
the primary tumor is associated with long disease free
and overall survival and low risk of relapse and metasta-
sis [2,3]. The impact of the immune score needs to be
evaluated in other tumor types given the universal
importance of the immune system in cancers. We have
focused on the prognostic and predictive value of the
immunoscore in patients with advanced melanoma trea-
ted with Ipilimumab in the previous 2-3 years, and cor-
related it with outcomes and response to the treatment.
Materials and methods
We have collected 190 FFPE metastatic samples from mel-
anoma patients treated with Ipilimumab, using the last
lesion excised before the treatment: lymph node involve-
ment or distant metastatic sites. We are characterizing the
immunescore with the expression of CD3, CD8, CD20,
Foxp3, by immunohistochemistry and evaluated correlation
with clinical outcome. Serial sections (3-4 micron in thick-
ness) have been stained with each marker and counter-
stained with H/E. Moreover, one section has been stained
with a multiplex of all markers including tumor marker for
melanoma (S100). All slides will be digitized on a Leica
SCN-400 system, and the results will be quantified by
assessing the density of different cellular immune popula-
tion at the center and invasive margin of the tumor using a
digital images analysis application (Definiens Architect
XD). The markers expression will be subsequently matched
with the most important clinical information about all the
patients.
Results
We have considered the clinical benefit from treatment
with Ipilimumab as the parameter for evaluating the effec-
tiveness of immunescore. The treatment has been consid-
ered as effective if a patient met a partial or complete
response, or had stable disease for more than 6 months
from the start of therapy, or with an overall survival > 1
year. The evaluation of prognostic and predictive power of
the immunoscore, in patients with metastatic melanoma,
treated with ipilimumab, are nearing completion and
definition.
Conclusion
We believe that the immunescore is key as prognostic and
predictive markers for immunotherapies in metastatic
melanoma.
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